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Sir, 
I would like to bring your attention to a number of significant
errors in the above article which are extremely misleading, both in
terms of the clinical effectiveness and cost of the drugs evaluated.
For ease of reference I have listed where mistakes have been made
below: 
Table 1 Gemcitabine is also licensed for treatment of advanced
bladder cancer (muscle invasive Stage IV tumours with and
without metastases) in combination with cisplatinum. 
Paclitaxel is also licensed for the treatment of non small cell
lung cancer (NSCLC) 
Docetaxel is also licensed for the treatment of second line
NSCLC. 
The table, as it stands, is incomplete and misleading about the
licensed indications of these drugs. 
Table 1 The costs have been calculated on a ‘per cycle basis’. 
The costs of Gemcitabine per cycle is listed as £1030, and the cost
of Vinorelbine £175 – suggesting that Gemcitabine is approximately
6 times as expensive as Vinorelbine on a per cycle basis. The actual
costs are in fact similar (for a cycle or course of treatment) and the
table should therefore be corrected, so that 3 infusions of
Gemcitabine are not compared to one infusion of Vinorelbine. 
Table 3 The effectiveness of new treatment scale claims that
Vinorelbine/Cisplatin has a 3–6 month survival advantage over
Cisplatin in first line NSCLC, with strength of evidence alpha +. It
would be interesting to see on what data this claim is based. There is
no mention of the comparable trial of Gemcitabine/Cisplatin vs
Cisplatin – in the first line setting, which should be included here as it
showed a significant survival advantage (P = 0.004). Added to which
39% one year survival for the Gemcitabine/Cisplatin combination is
not surpassed by any similar Vinorelbine/Cisplatin combinations. 
It is also worth noting that in the only comparative trial where
Gemcitabine/Cisplatin and Vinorelbine/Cisplatin have been
compared (although admitedly not compared head to head) the
Gemcitabine/Cisplatin arm appeared extremely favourable to 
the Vinorelbine/Cisplatin arm in terms of survival, where the
Vinorelbine/Cisplatin arm was dropped at the interim analysis
stage due to inferior efficacy. 
Gemcitabine has no licence for the second-line treatment of
NSCLC and this statement is therefore incorrect and should be
removed, added to which there are no randomized data to support
this effectiveness claim in the second line setting. 
There are a number of tumour types where new treatments are
available that have not been listed in the table such as pancreatic
cancer, bladder cancer and glioblastoma multiforme. 
These are the major inaccuracies. 
It is also worth commenting that whilst survival is often consid-
ered the most important endpoint in clinical trials, tumour types
which are notoriously chemoresistant such as NSCLC, pancreatic
cancer, and renal cancer can be discriminated against by using a
generic ranking scale which compares relatively chemosensitive
disease such as ovarian cancer, with those where survival benefits
may be hard to show, but where improvement in quality of life
may be just as important. 
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Sir, 
Neither the use of gemcitabine in bladder cancer nor the use of
docetaxel in non small cell lung cancer NSCLC were licensed
for these indications in the UK at the time of writing or
preparing the manuscript. More importantly there had been no
demand from clinicians locally to use these products in these
indications. This also explains the omission of paclitaxel treat-
ment for NSCLC (licensed Nov 1998). It should be noted that in
our next meeting to appraise new anticancer agents we will be
considering the use of gemcitabine plus cisplatin in bladder
cancer. 
Cost per cycle 
Price does not affect a rating a drug receives. We would concede
that if used as a price comparison for different treatments Table 1
could be misleading. However it would be extremely unwise to do
this for several reasons including the variability in pricing between
institutions and over time depending on the level of discount and
the variant regimens of the different drugs used. 
There is a good reason why the vinorelbine price per week is
given. At the time of writing (and currently) the dosage schedules
used for this drug are more variable than most and include once
weekly continuous treatment – with such a treatment, the appro-
priate cycle length is very hard to define. 
Relative effectiveness of vinorelbine 
There are many trials of vinorelbine in NSCLC that could be
considered when appraising its efficacy. Probably the two most
relevant are the following. A large trial (n = 612) by Chevalier et al
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